Lv61
1920 积分 2023-06-20 加入
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
6天前
已完结
Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
7天前
已完结
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
7天前
已完结
Activation of autophagy as a strategy to overcome Osimertinib-resistance in non-small cell lung cancer
9天前
已完结
Systemic therapy for brain metastases: a changing landscape
16天前
已完结
Advances in Systemic Therapy for Lung Cancer
24天前
已关闭
Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis
24天前
已关闭
Overall survival assessment in cancer drug trials: a luxury or a necessity?
26天前
已完结
Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies
27天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
1个月前
已完结
皖公网安备34019202002308
